Online sales of prescription drugs chaos exposure, the billion-dollar drug retail market has come

Online sales of prescription drugs trapped in the whirlpool
Around the sale of prescription drugs outside the hospital, recently, the news of buying prescription drugs online with pet dogs has attracted attention from outside the industry. The compliance and safety issues of online prescription drugs have once again sparked a hot debate. Under the general trend of prescription outflow, in the end, which method of taking prescriptions has the most potential for development, it is worth thinking and paying attention.
According to People's Daily, there are reporters investigating 20 online pharmacies and third-party platforms that provide drug trading services, 17 of which can purchase prescription drugs. In the absence of a prescription, the reporter used a photo of a pet dog as a prescription to successfully place an order; a minimum of 10 mg of a prescription drug that can cause a child's death, the "atropine sulfate tablet", can be used once without a prescription. Online shopping for multiple bottles. It can be said that a test by a media reporter exposed the problem that the current online prescription drugs are not small, such as prescription authenticity and prescription review.
Article 2 of the “Administrative Measures for the Classification of Prescription Drugs and Over-the-Counter Drugs” stipulates that prescription drugs must be adjusted, purchased and used with the prescription of a practicing physician or practicing assistant physician; Article 18 of the Measures for the Supervision and Administration of Drug Distribution stipulates: Pharmaceutical retail enterprises shall sell by prescription Prescription drugs, licensed pharmacists or other pharmacy technicians who are qualified according to law shall be listed and sold out. According to the relevant regulations, the prescription is true and effective, and the pharmacy technicians such as licensed pharmacists review the prescription according to the procedure, which is the two necessary links for patients to obtain prescription drugs. However, the current lack of two links is almost like "the elephant in the room", which is obvious. On the one hand, the compliance of prescription drug sales is generally low; on the other hand, the policy pressure to comply with the sale of prescription drugs continues to increase, under the pressure of double pressure, it is crucial to create a regulatory ecology of prescription drug sales.
100 billion prescription drug retail market to undertake pain points
At present, China's medical reform has brought out a series of new policies, such as medical insurance control fees, consistency evaluation, two-vote system, and 4+7 quantity procurement.
A number of research institutes have said that the era of "high premium" of drugs is about to pass, the price of drugs is falling, the profits of pharmaceutical companies are being diluted, and the high cost of marketing makes drug companies have to face "patent cliffs" and "channel barriers." At the time, look for new market opportunities in the fierce market competition. In the case of the original research drug that is gradually replaced by generic drugs in the hospital market, the vice president of Takeda Greater China believes that “the brand drugs that slowly lose the hospital market need to have innovative business strategies, and the retail channels are likely to become the original drug products. One of the ways to preserve the value of the product. The two certificates are integrated, the process is simplified, the medical insurance is fixed, the medical insurance co-ordination pilot is released, and the prescription outflow will benefit the sales growth of the retail market for a long time."
With reference to international experience, the separation of medicines is the general direction of China's medical reform. Prescription drugs are gradually flowing from hospitals to retail markets. Further expansion of the retail market is an inevitable outcome of reform. According to market research institutions, the total size of the prescription drug market in China will reach 189 billion yuan in 2020, and the prescription outflow of hospitals will account for about one-fifth of the total prescription. The scale of the prescription outflow market in China will be close to 400 billion yuan, and the prescription drug retail market. The sales volume will exceed 150 billion yuan.
Fu Gang, vice president of China Pharmaceutical Business Association and chairman of Baiyang Pharmaceutical Group, said that retail pharmacies in China currently have four major pain points – prescription sources, medical insurance docking, logistics specifications, and pharmacy services. After the four core issues are resolved, He believes that retail pharmacies will assume the historical responsibility for the sale of prescription drugs.
Create a 100 billion prescription drug retail platform
Based on this, on June 29, at the China Pharmaceutical Retail Industry Conference in 2019, supported by the China Pharmaceutical Business Association and Baiyang Pharmaceutical Group, nearly 30 mainstream pharmaceutical industrial companies jointly announced the launch of the “100 billion prescription drug retail platform”.
Cypress Blue was informed at the scene that in the future, the platform will play the role of prescription drug supply and efficient synergy of mainstream pharmaceutical companies around the world. Baiyang Pharmaceutical Group will participate in the platform through omni-channel coverage, multi-category synergy and digital marketing capabilities. Multi-party companies provide corresponding services. In the view of Fugang, the value of the hospital is gradually returning. The hospital is still a strategic fortress for the health industry. It is a medical decision-making center, a patient flow hub, and a source of industrial innovation. Retail enterprises that do not establish a stable connection with the hospital can only struggle in the Red Sea. . Taking the hospital as the starting point, unlike the previous pharmaceutical commercial enterprises, Baiyang is a commercial platform, in-depth study of the links of medical institutions, retail enterprises and industrial enterprises, helping pharmaceutical companies to advance advanced pharmaceutical products and medical technology through excellent retail. The channel enters the application scenario. He further introduced that for upstream industrial enterprises, the cost of establishing a retail team for several products is relatively high. As an organizer of the “100 billion prescription drug retail platform”, Baiyang Pharmaceutical Group hopes to help upstream enterprises to develop appropriate systems through platform mechanisms. Retail strategy to achieve digital precision marketing in the retail market. At the same time, for downstream retail pharmacies, Baiyang will also help retail pharmacies design overall solutions from the aspects of information technology, supply chain and resource docking.
In view of the pain points of the current retail terminal sales of prescription drugs, Baiyang Pharmaceutical Group provides packaged services such as prescription sources, pharmaceutical services, and logistics specifications for retail pharmacies through platforms such as easy-to-review.
Under the trend of 100 billion prescription outflows, the platform to solve the prescription pain point of prescription drugs will become the choice of a group of pharmaceutical industry enterprises.